… increases with time, more and more efforts are made to pave a way out for the therapeutic …
in COVID-19 patients, it drives our focus onto the signaling cascades of the JAK/STAT pathway…

… Nafamostat is another TMPRSS2 inhibitor that in a mouse model of COVID-19 reduced
SARS-CoV-2 pulmonary infection [17]. A neutralizing antibody directed against the viral S protein …

… COVID-19 test result. Another TMPRSS2 inhibitor with therapeutic potential for treatment of
COVID-19 is … drug for indications unrelated to corona virus and used in Asian countries as a …

… result in a reduction in the cytokine storm and alleviate the severity of COVID-19. Inhibition
of NF-κB pathway has a potential therapeutic role in alleviating the severe form of COVID-19. …

… other potential JAKinibs and novel anti-inflammatory combination therapies that affect the
JAK-STAT pathway in patients with COVID-19. Since the combination of MTX and baricitinib …

… , and DHA/EPA, pasireotide), as well as inhibitors targeted toward molecular mediators of
the maladaptive COVID-19 immune response (eg, IL-6, TNF-α, IL-17, JAK, and CDK9). …

… downregulating a key inhibitory pathway, while simultaneously taking advantage of p38
activity to replicate. Therapeutic inhibition of p38 could therefore attenuate COVID-19 infection. …

… with the mortality of COVID-19 patients. Both the … treatment available for COVID-19, but
scientists have purposed several treatment options including cytokine inhibitors, JAK inhibitors…

… syndrome-associated coronavirus-2 (… pathway activation and has anticoagulant effects.
In this study, the first time a lectin-pathway inhibitor was used to treat COVID-19, six COVID-19 …

… inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical
cellular signaling pathways … SARS-CoV-2 and the COVID-19 pandemic, and then focuses on …